- Home
- IGA vs ALEC Comparison
IGA vs ALEC Comparison
Compare IGA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGA
- ALEC
- Stock Information
- Founded
- IGA 2005
- ALEC 2013
- Country
- IGA United States
- ALEC United States
- Employees
- IGA N/A
- ALEC N/A
- Industry
- IGA Investment Managers
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGA Finance
- ALEC Health Care
- Exchange
- IGA Nasdaq
- ALEC Nasdaq
- Market Cap
- IGA 147.6M
- ALEC 174.3M
- IPO Year
- IGA N/A
- ALEC 2019
- Fundamental
- Price
- IGA $9.67
- ALEC $1.87
- Analyst Decision
- IGA
- ALEC Buy
- Analyst Count
- IGA 0
- ALEC 6
- Target Price
- IGA N/A
- ALEC $11.75
- AVG Volume (30 Days)
- IGA 42.3K
- ALEC 471.2K
- Earning Date
- IGA 01-01-0001
- ALEC 02-26-2025
- Dividend Yield
- IGA 8.93%
- ALEC N/A
- EPS Growth
- IGA N/A
- ALEC N/A
- EPS
- IGA N/A
- ALEC N/A
- Revenue
- IGA N/A
- ALEC $61,508,000.00
- Revenue This Year
- IGA N/A
- ALEC N/A
- Revenue Next Year
- IGA N/A
- ALEC $0.12
- P/E Ratio
- IGA N/A
- ALEC N/A
- Revenue Growth
- IGA N/A
- ALEC N/A
- 52 Week Low
- IGA $7.77
- ALEC $1.55
- 52 Week High
- IGA $8.88
- ALEC $7.58
- Technical
- Relative Strength Index (RSI)
- IGA 63.98
- ALEC 54.66
- Support Level
- IGA $9.59
- ALEC $1.71
- Resistance Level
- IGA $9.70
- ALEC $1.86
- Average True Range (ATR)
- IGA 0.13
- ALEC 0.10
- MACD
- IGA 0.02
- ALEC 0.04
- Stochastic Oscillator
- IGA 78.00
- ALEC 84.21
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.